Literature DB >> 9083079

Dimerization of midkine by tissue transglutaminase and its functional implication.

S Kojima1, T Inui, H Muramatsu, Y Suzuki, K Kadomatsu, M Yoshizawa, S Hirose, T Kimura, S Sakakibara, T Muramatsu.   

Abstract

Midkine (MK), a retinoic acid-inducible growth/differentiation factor, serves as a substrate for tissue transglutaminase (Kojima, S. , Muramatsu, H., Amanuma, H., and Muramatsu, T. 1995. J. Biol. Chem. 270, 9590-9596). Upon incubation with transglutaminase MK forms multimers through cross-linkages. Here, we report the following results. 1) Heparin potentiated the multimer formation by MK. 2) The N- and C-terminal half domains each formed a dimer through the action of transglutaminase. 3) Gln42 or Gln44 in the N-terminal half and Gln95 in the C-terminal half served as amine acceptors in the cross-linking reaction, as judged from the incorporation of putrescine into whole MK or each half domain, and the competitive inhibition of the cross-linking by MK-derived peptides containing Gln residue(s). The strongest inhibition was obtained with Ala41-Pro51. 4) This peptide abolished the biological activity of MK to enhance the plasminogen activator activity in bovine aortic endothelial cells. The inhibition was limited against the MK monomer, and not seen against the MK dimer, separated by gel filtration chromatography. These results suggest that dimer formation through transglutaminase-mediated cross-linking is an important step as to the biological activity of MK.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083079     DOI: 10.1074/jbc.272.14.9410

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Midkine in host defence.

Authors:  A Gela; S Jovic; S L Nordin; A Egesten
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 3.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 4.  Pleiotrophin: Activity and mechanism.

Authors:  Xu Wang
Journal:  Adv Clin Chem       Date:  2020-03-12       Impact factor: 5.394

5.  Solution structure of midkine, a new heparin-binding growth factor.

Authors:  W Iwasaki; K Nagata; H Hatanaka; T Inui; T Kimura; T Muramatsu; K Yoshida; M Tasumi; F Inagaki
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

6.  Protein-bound carbohydrates on cell-surface as targets of recognition: an odyssey in understanding them.

Authors:  T Muramatsu
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

7.  Tissue transglutaminase is a negative regulator of monomeric lacritin bioactivity.

Authors:  Francisco Velez V; Jeffrey A Romano; Robert L McKown; Kari Green; Liwen Zhang; Ronald W Raab; Denise S Ryan; Cindy M L Hutnik; Henry F Frierson; Gordon W Laurie
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-01       Impact factor: 4.799

Review 8.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

9.  Functional divergence of two zebrafish midkine growth factors following fish-specific gene duplication.

Authors:  Christoph Winkler; Matthias Schafer; Jutta Duschl; Manfred Schartl; Jean-Nicolas Volff
Journal:  Genome Res       Date:  2003-05-12       Impact factor: 9.043

10.  Cellular expression of midkine-a and midkine-b during retinal development and photoreceptor regeneration in zebrafish.

Authors:  Anda-Alexandra Calinescu; Thomas S Vihtelic; David R Hyde; Peter F Hitchcock
Journal:  J Comp Neurol       Date:  2009-05-01       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.